Form 4: REGENXBIO Director Exercises Options, Covers Taxes

REGENXBIO Director Kenneth T. Mills exercised 225,000 stock options and simultaneously disposed of shares to cover the exercise price and taxes.

Summary

• Kenneth T. Mills, a Director at REGENXBIO Inc. (RGNX), exercised 225,000 stock options on January 27, 2026, at an exercise price of $13.09 per share.
• These options were originally granted on January 28, 2016, with vesting commencing on January 28, 2017, and expiring on January 28, 2026.
• Concurrently, 221,753 shares of common stock were disposed of at a price of $13.41 per share to satisfy the exercise price and cover tax obligations.
• This transaction was executed pursuant to a Rule 10b5-1 plan and did not involve any open-market sale of securities.
• Following these transactions, Kenneth T. Mills beneficially owns 486,118 shares of REGENXBIO Inc. common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a significant portion of shares was sold to cover costs, the director's decision to exercise options rather than let them expire can be seen as a minor positive signal of confidence.

Positives

• The exercise of stock options by a director can be interpreted as a signal of continued confidence in the company's long-term prospects, even when a portion is sold to cover taxes and exercise costs.

Negatives

• A significant portion of the exercised options (221,753 out of 225,000 shares) was immediately disposed of to cover the exercise price and tax liabilities, resulting in a minimal net increase in direct beneficial ownership from this specific option exercise.

Future Outlook

na

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that Form 4 filings provide transparency into insider trading activities, which can offer insights into management's perspective on the company's value. However, this specific filing, detailing a routine option exercise and 'sell to cover' transaction, typically does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders gain transparency into the director's equity holdings and compensation management. The transaction itself is unlikely to have a material impact on the company's operational or strategic direction.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Transaction, Stock Options, Director, Beneficial Ownership, Equity Compensation